Rule 3.19A.3

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Recce Pharmaceuticals Ltd (**Company**)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Alistair McKeough
Date of last notice	16 May 2025
Date that director ceased to be director	6 November 2026

Part 1 – Director's relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	**Number & class of securities**
Finn Frist Pty Ltd as trustee for the AZM Superannuation Fund of which Mr McKeough is a director and shareholder of the trustee and a beneficiary of the trust (**Finn Frist Pty Ltd**)	Finn Frist Pty Ltd 1. 30,287 fully paid ordinary shares
Amabel Pty Limited as trustee for the McKeough Family Trust of which Mr McKeough is a director of the trustee and a beneficiary of the trust (**Amabel Pty Limited**)	Amabel Pty Limited 1. 1,125,000 unlisted options each exercisable at $1.56, expiring 15 November 2027 2. 1,000,000 unlisted options each exercisable at $0.80, expiring 14 November 2029

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A